Gantenerumab

About Chugai Pharmaceutical

Chugai Pharmaceutical's mission is to create innovative, best-in-class therapeutics that contribute to human health worldwide, with a strategic focus on oncology and niche specialty areas. Its defining achievement is the construction of a highly successful, decades-long strategic alliance with Roche, which provides a unique two-way pipeline flow, global scale, and financial stability. The company's strategy centers on maintaining a powerful independent R&D engine to generate proprietary assets while simultaneously co-developing and commercializing Roche's global portfolio in its key markets. This model has established Chugai as Japan's premier biopharmaceutical innovator and a vital node in Roche's global network.

About Roche

Roche is a global healthcare leader with a unique dual-pillar strategy combining its Pharmaceuticals and Diagnostics divisions to address the full patient journey. Under CEO Thomas Schinecker, the company focuses on preventing disease through early identification, halting progression via targeted therapies, and restoring health with curative medicines. With a market cap of ~$256B, it leverages its integrated platform to drive innovation in oncology, neurology, immunology, and infectious diseases, while pursuing sustainable, long-term growth.

Therapeutic Areas

Other Alzheimer's Disease Drugs